In testing response of PCa cell lines to trastuzumab (anti-HER2) and cetuximab (anti-EGFR), Andersson et al did not observe additional effects of addition of cetuximab to trastuzumab. The gene discussed is EGFR; the disease is posterior cortical atrophy.